18.5 Calcium Channel Blockers

Calcium Channel Blockers

Calcium channel blockers (CCBs) treat hypertension, angina, and certain arrhythmias by preventing calcium from entering cardiac and vascular smooth muscle cells. The result is vasodilation, lower blood pressure, and reduced cardiac workload. Different CCB classes have distinct effects on the heart versus the blood vessels, so knowing which class does what is essential for safe nursing practice.

Mechanism of Action

CCBs block L-type voltage-gated calcium channels found in vascular smooth muscle cells and cardiomyocytes. When calcium can't flow into these cells, intracellular calcium concentration drops, and the muscle relaxes.

This produces two main categories of effect:

Vascular effects:

• Peripheral arteries and arterioles dilate, which decreases systemic vascular resistance (SVR) and lowers blood pressure
• Reduced SVR means less afterload on the heart, so the heart doesn't have to pump as hard

Cardiac effects:

• Negative inotropic effect (decreased contractility) reduces the force of each heartbeat
• Negative chronotropic effect (decreased heart rate) slows conduction through the SA and AV nodes
• Both effects lower myocardial oxygen demand, which is why CCBs help with angina

CCBs also dilate coronary arteries, improving oxygen delivery to the myocardium. This combination of decreased oxygen demand and increased oxygen supply is what makes them effective for angina relief.

Cellular Mechanisms and Physiological Effects

At the cellular level, CCBs disrupt excitation-contraction coupling. Normally, calcium enters through voltage-gated channels during an action potential and triggers muscle contraction. By blocking that calcium influx, CCBs prevent the contraction signal from completing.

• In vascular smooth muscle, this means relaxation and vasodilation
• In cardiac muscle, this means weaker contractions and slower conduction
• The effect on the cardiac conduction system (especially the AV node) also gives certain CCBs antiarrhythmic properties, which is why verapamil and diltiazem are used for rate control in atrial fibrillation and other supraventricular tachycardias

Classes of Calcium Channel Blockers

Not all CCBs are the same. The two major categories differ significantly in where they act, and that determines how you use them clinically.

Dihydropyridines (amlodipine, nifedipine)

• Potent peripheral vasodilators with minimal direct cardiac effects
• Primarily used for hypertension
• Because they don't significantly slow heart rate or reduce contractility, they're generally safer to combine with beta-blockers
• Reflex tachycardia can occur, especially with short-acting nifedipine, because the rapid drop in blood pressure triggers a compensatory increase in heart rate

Non-dihydropyridines have two subclasses:

• Benzothiazepines (diltiazem): Provide moderate vasodilation and moderate cardiac effects. Used for hypertension, angina, and rate control in certain arrhythmias. Think of diltiazem as the "middle ground" CCB.
• Phenylalkylamines (verapamil): Minimal peripheral vasodilation but the strongest cardiac effects of any CCB. Used for angina, hypertension, and supraventricular arrhythmias. Verapamil has the most pronounced effect on the AV node.

Side Effects and Drug Interactions

Common side effects:

• Peripheral edema (especially with dihydropyridines like amlodipine): caused by arteriolar dilation, not fluid overload, so diuretics won't help much
• Headache, dizziness, and flushing (all related to vasodilation)
• Constipation: particularly common with verapamil because calcium channels in GI smooth muscle are also affected
• Bradycardia: more common with non-dihydropyridines (verapamil, diltiazem) due to their effects on the SA and AV nodes

Key drug interactions:

• CYP3A4 inhibitors (erythromycin, ketoconazole, grapefruit juice) increase CCB blood levels, raising the risk of toxicity and exaggerated side effects
• CYP3A4 inducers (rifampin, phenytoin) decrease CCB blood levels, potentially making the drug ineffective
• Beta-blockers + non-dihydropyridines: Both slow heart rate and reduce contractility. Combining them increases the risk of severe bradycardia, heart block, and heart failure. This combination requires very careful monitoring or may be avoided entirely.
• Verapamil or diltiazem + digoxin: These CCBs raise digoxin levels by reducing its renal clearance. Monitor digoxin levels closely and watch for signs of digoxin toxicity (nausea, visual changes, bradycardia).

Nursing Considerations

Assessment and monitoring:

1. Check blood pressure and heart rate before each dose. Hold the medication and notify the provider if the heart rate is below 60 bpm or blood pressure is below the facility's parameters (commonly systolic < 90 mmHg).
2. Assess for peripheral edema by checking ankles and feet daily. Document any changes.
3. Monitor for signs of hypotension: dizziness, lightheadedness, or near-syncope.
4. Review the patient's medication list for interacting drugs, especially beta-blockers, digoxin, and CYP3A4 inhibitors or inducers.
5. For patients on verapamil, ask about bowel habits and assess for constipation.

Patient education:

• Take the medication at the same time every day, exactly as prescribed. Don't skip doses or double up.
• Avoid grapefruit juice entirely while on CCBs. Grapefruit inhibits CYP3A4 in the gut, which can cause dangerously high drug levels.
• Rise slowly from sitting or lying positions to reduce the risk of orthostatic hypotension.
• Report persistent ankle swelling, dizziness, unusually slow heartbeat, or constipation to the healthcare provider.
• Teach patients how to take their own pulse. They should know to contact their provider if their resting heart rate drops below 60 bpm or if they feel palpitations.
• Reinforce lifestyle modifications for blood pressure management: reduced sodium intake, regular physical activity, weight management, and limiting alcohol.